PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Similar other expenses growth to CRVO's 100.00%. Walter Schloss would investigate industry patterns.
752.87%
Operating expenses growth above 1.5x CRVO's 251.41%. Michael Burry would check for inefficiency.
752.87%
Total costs growth above 1.5x CRVO's 15.98%. Michael Burry would check for inefficiency.
22.99%
Interest expense change of 22.99% while CRVO maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
-552.87%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-552.87%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
675.86%
Tax expense change of 675.86% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
-675.86%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-2175.00%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-2175.00%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
-66.67%
Share count reduction while CRVO shows 2.84% change. Joel Greenblatt would examine strategy.
-66.67%
Diluted share reduction while CRVO shows 2.84% change. Joel Greenblatt would examine strategy.